AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23356247
Drug: High-dose ω-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ω-3 fatty acid ethyl esters (3.2 g/day)
Trial: 8071277
Drug: Nefazodone 100-500
RxNorm normalized name: nefazodone
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone 100-500 mg/day
Trial: 8071277
Drug: Nefazodone 50-250
RxNorm normalized name: nefazodone
DrugBank: Nefazodone (DB01149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nefazodone 50-250 mg/day
Trial: 8071277
Drug: Imipramine 50-250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 50-250 mg/day
Trial: 3289961
Drug: Methylcholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcholine inhalation
Trial: 26628263
Drug: Ischemic compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ischemic compression via physical therapy (administered three times for 60 seconds each with 30 seconds rest)
Trial: 21445092
Drug: Degarelix (s.c.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (s.c., 240/80 mg, n=207)
Trial: 21445092
Drug: Degarelix (s.c.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (s.c., 240/160 mg, n=202)
Trial: 11028723
Drug: IT tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IT tetracaine 15 mg + neostigmine 50 microg
Trial: 11028723
Drug: IT tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IT tetracaine 15 mg + neostigmine 100 microg
Trial: 11028723
Drug: IT tetracaine
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IT tetracaine 15 mg
Trial: 8452169
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg once a day for 7 days
Trial: 24446523
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dolutegravir (DTG) 50 mg BID
Trial: 22260745
Drug: 26% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26% NaCl and heparin
Trial: 10084064
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin
Trial: 11076326
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine (T4) supplementation (10 or 20 micrograms/kg; intravenous or nasogastric tube) for 21 days
Trial: 1574972
Drug: Crystalloid volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid volume loading (10 ml.kg‐1 b.w.)
Trial: 2859650
Drug: Somatostatin-28 (SS-28)
RxNorm normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin-28 (SS-28) infusion
Trial: 2859650
Drug: Somatostatin-14 (SS-14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin-14 (SS-14) infusion at 75 pmol/kg-h
Trial: 17873677
Drug: 108 mg
RxNorm normalized name: camphor 108 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 108 mg extended-release methylphenidate (osmotic release oral system [OROS])
Trial: 15857282
Drug: N-chlorotaurine (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-chlorotaurine (1% aqueous solution)
Trial: 9382121
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alendronate
Trial: 6232583
Drug: Hydrochlorothiazide 50
RxNorm normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 50 mg/day (group II, n = 19)
Trial: 25215557
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg/d)
Trial: 25215557
Drug: Joint calcium
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint calcium (1000 mg/d) and vitamin D (50000 IU/wk)
Trial: 1461853
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of intravenous Augmentin (amoxycillin 250 mg and clavulanic acid 125 mg)
Trial: 1461853
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of intravenous Augmentin (amoxycillin 250 mg and clavulanic acid 125 mg) every 8 hours
Trial: 1461853
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of intravenous Augmentin
Trial: 1461853
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of intravenous Augmentin
Trial: 19404632
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination (200 mg artesunate + 540 mg amodiaquine)
Trial: 19404632
Drug: Loose combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose combination (200 mg artesunate + 612 mg amodiaquine)
Trial: 16188428
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (group A)
Trial: 16188428
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg (group B)
Trial: 16188428
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg as sub‐mucosal injection (group C)
Trial: 3838425
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (13 g of carbohydrate)
Trial: 3838425
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk (13 g of carbohydrate)
Trial: 3838425
Drug: Skim milk
RxNorm normalized name: skim milk
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skim milk (13 g of carbohydrate)
Trial: 25335963
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) plus treatment as usual
Trial: 26491889
Drug: Ialuril Soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ialuril Soft Gels in hypo-extreme group
Trial: 22752862
Drug: Fidaxomicin 200
RxNorm normalized name: fidaxomicin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin 200 mg twice per day for 10 days
Trial: 22752862
Drug: Vancomycin 125
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg 4 times per day for 10 days
Trial: 9580856
Drug: Iodine-123 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodine-123 administration only (G0)
Trial: 12517685
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg)
Trial: 25960375
Drug: PCI +
RxNorm normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI + Optimal Medical Therapy (OMT)
Trial: 24094693
Drug: Medium-titration group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-titration group (150mg/day every 4 days)
Trial: 19001472
Drug: Culotte stenting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culotte stenting with drug-eluting stents
Trial: 12622302
Drug: Routine GP
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine GP treatment
Trial: 10861652
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment continued for 2 years
Trial: 9144683
Drug: paclitaxel/cisplatin/G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: paclitaxel/cisplatin/G-CSF
Trial: 3131406
Drug: topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical nasal treatment
Trial: 24949547
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement group (SG)
Trial: 22610268
Drug: Midodrine 10-30
RxNorm normalized name: midodrine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 10-30 mg/day
Trial: 327987
Drug: Baclofen (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (70 to 80 mg daily maximum, titrated)
Trial: 31793473
Drug: Universal adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal adhesive application with no treatment (control)
Trial: 19453031
Drug: On-demand therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand therapy with omeprazole 20 mg (Group A1)
Trial: 15060418
Drug: 20 microg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 microg/min t‐PA infusion
Trial: 15060418
Drug: 40 microg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 microg/min t‐PA infusion
Trial: 2194715
Drug: terbinafine (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine (125 mg b.i.d.)
Trial: 2194715
Drug: griseofulvin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: griseofulvin (500 mg b.i.d.)
Trial: 353623
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (750 mg per day)
Trial: 353623
Drug: Calcium dobesilate
RxNorm normalized name: CALCIUM DOBESILATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium dobesilate (1,000 mg per day)
Trial: 28040660
Drug: Standard chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemoradiotherapy (SFX) with cisplatin (100 mg/m2 IV × 3)
Trial: 26237830
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with oral sanhuangwuji powder, ginger-partitioned acupoint stimulation at zusanli (ST 36), and ARDs
Trial: 23774436
Drug: Gatifloxacin 400
RxNorm normalized name: gatifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg daily doses
Trial: 16942472
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment plus progressive muscular relaxation (PMR) exercises
Trial: 14964492
Drug: Flap surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flap surgery and laser treatment using an energy level of 0.8 W
Trial: 12237921
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (CPT-11) 100 mg/m² over 90 minutes, Paclitaxel 175 mg/m² over 3 hours, Carboplatin AUC 5 over 30 minutes, administered on the first day of each 21-day cycle.
Trial: 12237921
Drug: Irinotecan (CPT-11),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (CPT-11), Paclitaxel, and Carboplatin combination therapy.
Trial: 7639224
Drug: 3 U
RxNorm normalized name: Carbon 13 urea
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Trial: 7639224
Drug: 6 U
RxNorm normalized name: vitamin E 6 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Trial: 2988589
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg/day
Trial: 29985265
Drug: ARV drugs
RxNorm normalized name: Arv-110 (protac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV drugs detected in HIV-uninfected young women
Trial: 29985265
Drug: ARV drugs
RxNorm normalized name: Arv-110 (protac)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV drugs detected in seroconverters
Trial: 29985265
Drug: HIV drug
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV drug resistance in seroconverters with genotyping results
Trial: 19825505
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Trial: 15601811
Drug: Encapsulated sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Encapsulated sumatriptan (100 mg)
Trial: 10352534
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol (E2) transdermal treatment 50 micrograms (TTS 50) continuously administered plus Medroxyprogesterone Acetate (MPA) 10 mg/die for twelve days a month (Group A)
Trial: 10352534
Drug: Conjugated Equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated Equine Estrogens (CEE) 0.625 mg/die continuously plus MPA for twelve days a month (Group B)
Trial: 10352534
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal 50 micrograms continuously plus MPA 2.5 mg/die continuously (Group C)
Trial: 10352534
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/die continuously plus MPA 2.5 mg/die continuously (Group D)
Trial: 1780205
Drug: 1.4 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 ml/kg of 95% ethanol, plus diluent
Trial: 30887865
Drug: Citalopram 4
RxNorm normalized name: citalopram 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 4 mg
Trial: 22779219
Drug: Topical gingival
RxNorm normalized name: Bos taurus gingiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gingival patch
Trial: 17656440
Drug: Caffeine capsules
RxNorm normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsules (dose = 5 mg kg(‐1)) and saline infusion ([ADR] = 0.62 nm)
Trial: 17656440
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and saline infusion ([ADR] = 0.29 nm)
Trial: 17656440
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules and ADR infusion ([ADR] = 1.19 nm)
Trial: 17656440
Drug: Caffeine capsules
RxNorm normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine capsules (dose = 5 mg kg(‐1)) and ADR infusion ([ADR] = 0.93 nm)
Trial: 16275937
Drug: PCF (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, FU 500 mg/m2 continuous infusion on days 2 through 6)
Trial: 16275937
Drug: CF (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF (cisplatin 100 mg/m2 on day 1 plus FU 1000 mg/m2 continuous infusion on days 1 through 5)
Trial: 8536900
Drug: Octreotide (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (25, 50, or 100 micrograms diluted in normal saline solution)
Trial: 27928851
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (control)
Trial: 26203643
Drug: Suprascapular nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suprascapular nerve block plus physical therapy (PT)
Trial: 11127934
Drug: Platelet glycoprotein
RxNorm normalized name: PLATELET GLYCOPROTEIN VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet glycoprotein IIb/IIIa inhibitors
Trial: 9521334
Drug: Abciximab therapy
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abciximab therapy
Trial: 10757081
Drug: Bestatin (ubenimex)
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bestatin (ubenimex) 10, 30, 90, and 180 mg/day for 60 days after BMT
Trial: 8353547
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (group I)
Trial: 20868559
Drug: LCAHFR combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCAHFR combined with FP chemotherapy
Trial: 17227978
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with gemcitabine
Trial: 25307976
Drug: Low-dose glucocorticoid
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose glucocorticoid treatment
Trial: 15572415
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections and pills
Trial: 14764753
Drug: T enanthate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate, 200 mg im every 2 weeks with placebo pills daily (T-only)
Trial: 14764753
Drug: T enanthate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T enanthate, 200 mg every 2 weeks with 5 mg finasteride daily (T+F)
Trial: 8989254
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 for 30 days (subgroup A)
Trial: 10146972
Drug: roxithromycin 150mg
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin 150mg twice daily
Trial: 10146972
Drug: cefaclor 250mg
RxNorm normalized name: CEFACLOR 250MG CAP
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cefaclor 250mg thrice daily
Trial: 31696598
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily (QD)
Trial: 31379311
Drug: Social Recovery
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social Recovery Therapy (SRT)
Trial: 26541060
Drug: 875 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 875 µg (35 000 IU) cholecalciferol (vitamin D3) per week
Trial: 25966665
Drug: Edoxaban (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (15 mg single oral dose)
Trial: 22243943
Drug: Normal protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal protein diet (NP, 1 g protein:2 g carbohydrate)
Trial: 22243943
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (LP, 1 g protein:4 g carbohydrate)
Trial: 12594876
Drug: Ventilator weaning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventilator weaning protocol (WP) + chlorhexidine 0.12% oral rinse administered twice daily
Trial: 9743218
Drug: Fc gamma
RxNorm normalized name: Recombinant, soluble, non-glycosylated version of fc gamma receptor iib
DrugBank: Valziflocept (DB17728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fc gamma receptor II (Fc gammaRII) and Fc gamma receptor III (Fc gammaRIII) expression on monocytes stained with specific monoclonal antibodies (IV.3 and 3G8)
Trial: 7848929
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (EA) with 0.1% bupivacaine, 0.01% morphine sulfate
Trial: 6088252
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg)
Trial: 25452446
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Trial: 23186975
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily (OD)
Trial: 14644397
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg QD
Trial: 17875305
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg QD
Trial: 11094868
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human IL-10 (rHuIL-10) at doses of 5, 10, or 20 micrograms/kg, administered subcutaneously, once daily for 28 days
Trial: 1770154
Drug: Haloperidol 10
RxNorm normalized name: haloperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 10 mg daily
Trial: 2871010
Drug: Haloperidol 20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 20 mg daily
Trial: 1554036
Drug: Plasma haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma haloperidol levels above 12 ng/ml
Trial: 30072213
Drug: BKV or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKV or CMV viral loads over 10,000 copies·mL‐1
Trial: 22298867
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 1500 mL of an isotonic solution per day for 6 days
Trial: 22298867
Drug: Home oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home oral hydration therapy of 1500 mL/d (subgroup A1)
Trial: 22298867
Drug: Home oral
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home oral hydration therapy of 2500 mL/d (subgroup A2)
Trial: 23815562
Drug: Olmesartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan (20 mg)